← back to search

Kristi Krebs

University of Tartu ·
Area of research
Genetics · Pharmacology
Research interest
Research interests include Genetic Associations and Epidemiology, Pharmacogenetics and Drug Metabolism, Genomics and Rare Diseases, and Genetics and Neurodevelopmental Disorders.
h-index
24
citations
4,171
works
87
NIH funding
primary concept
Medicine
email

Recent publications

Large-scale GWAS of strabismus identifies risk loci and provides support for a link with maternal smoking
Nature Communications 2025cited by 4position: middledoi
Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling
medRxiv 2024cited by 24position: middledoi
Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases
Nature Medicine 2023cited by 35position: middledoi
Stroke genetics informs drug discovery and risk prediction across ancestries
Nature 2022cited by 588position: middledoi
Genome-wide association meta-analysis identifies 48 risk variants and highlights the role of the stria vascularis in hearing loss
The American Journal of Human Genetics 2022cited by 70position: middledoi
Neandertal introgression partitions the genetic landscape of neuropsychiatric disorders and associated behavioral phenotypes
Translational Psychiatry 2022cited by 23position: middledoi
Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries
Nature 2022cited by 12position: middledoi
Stroke genetics informs drug discovery and risk prediction across ancestries
Research Square 2022cited by 10position: middledoi
Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology
Nature Genetics 2021cited by 1,563position: middledoi
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Science Translational Medicine 2020cited by 111position: middledoi
Global Frequencies of Clinically Important <i>HLA</i> Alleles and Their Implications For the Cost‐Effectiveness of Preemptive Pharmacogenetic Testing
Clinical Pharmacology & Therapeutics 2020cited by 55position: middledoi
Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions
Genetics in Medicine 2018cited by 99position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Reedik Mägi · University of Tartu3 papers (2018–2022)Volker M. Lauschke · Karolinska University Hospital2 papers (2018–2020) · 1 papers (2018–2018) · 1 papers (2022–2022) · 1 papers (2022–2022)Andres Metspalu · Broad Institute1 papers (2022–2022)Liming Li · AgriBio1 papers (2020–2020)Zhengming Chen · Population Council1 papers (2020–2020)Teresa Ferreira · Open Data Institute1 papers (2020–2020)Maarja Lepamets · University of Tartu1 papers (2018–2018)Kuang Lin · Children's Hospital of Philadelphia1 papers (2020–2020)Mart Kals · Science for Life Laboratory1 papers (2018–2018)Tõnu Esko · Jewish General Hospital1 papers (2022–2022)Jaak Vilo · European Molecular Biology Laboratory1 papers (2018–2018)Mari Nelis · University of Tartu1 papers (2022–2022)George Davey Smith · Laboratoire d’immunologie intégrative du cancer1 papers (2020–2020)Manuel A. Friese · Universität Hamburg1 papers (2022–2022)Benjamin M. Neale · Broad Institute1 papers (2020–2020)Stefan M. Gold · Universität Hamburg1 papers (2022–2022)Christian Otte · Centre for Mental Health1 papers (2022–2022)